AsthmaRAMICSNCT06732141
Remote Anxiety Management for ICS-resistant Asthma Study
A study testing Personalized Telephone-Based Psychological Support in people with Asthma, run by First Affiliated Hospital of Ningbo University at 11 sites in China.
Trial summary
This study, the Remote Anxiety Management for ICS-resistant Asthma Study (RAMICS), explores strategies to improve medication adherence and anxiety management in asthma patients who are resistant to using inhaled corticosteroids (ICS) due to anxiety. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Asthma
- What is being tested?
- Personalized Telephone-Based Psychological Support
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 216 participants
- Where
- 11 sitesChina
- Study dates
- 13 Dec 2024to 30 Jun 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age Requirement:
- Participants must be aged 18 to 80 years, ensuring they are adults capable of making decisions and responding effectively to interventions.
- Diagnosed Asthma:
- Diagnosis must meet the criteria of the Global Initiative for Asthma (GINA) or the American Academy of Asthma guidelines, with at least one confirmed diagnosis by a specialist in the past six months.
- Asthma severity must range from mild to moderate persistent, in the chronic management phase, excluding patients in acute exacerbation phases for clearer evaluation of adherence and intervention effects.
- ICS Treatment History:
Show all 17Show fewer
- Participants must have been on inhaled corticosteroid (ICS) therapy for at least six months, ensuring sufficient treatment history for adherence and effect evaluation.
- No major changes to asthma control medication regimen in the past six months, ensuring adherence and intervention outcomes are not confounded by treatment changes.
- Poor Medication Adherence:
- Identified using the Medication Adherence Report Scale (MARS-10), with an average score <4.5, indicating suboptimal adherence.
- Presence of Anxiety Symptoms:
- Confirmed through the Hamilton Anxiety Rating Scale (HAMA), with a score ≥14, indicating clinically significant anxiety.
- Anxiety symptoms must be related to asthma treatment, particularly concerns about ICS side effects or long-term use, ensuring the psychological intervention targets relevant issues.
- Ability to Communicate by Phone:
- Participants must have stable access to a phone and be willing to engage in telephone-based psychological interventions.
- Stable Health Condition:
- Asthma status must be stable, with no acute exacerbations or significant changes in the past month.
Who cannot join
- Severe Psychiatric or Cognitive Disorders:
- Diagnosis of major psychiatric disorders, such as major depressive disorder, bipolar disorder, schizophrenia, or other severe mental illnesses within the past six months, based on DSM-5 criteria.
- Presence of cognitive impairments or neurological conditions, such as dementia or post-stroke complications, that may affect comprehension or adherence to the intervention.
- Current psychiatric treatment involving antipsychotics, antidepressants, or sedatives that could interfere with the intervention's outcomes.
- Substance Abuse or Dependence:
- History of alcohol or drug abuse within the past six months, including but not limited to opioids, benzodiazepines, or illicit substances.
Show all 21Show fewer
- Severe Comorbidities:
- Uncontrolled respiratory or cardiovascular conditions, such as chronic obstructive pulmonary disease (COPD), bronchiectasis, interstitial lung disease, heart failure, or uncontrolled hypertension, that could significantly impact asthma control and overall health.
- Chronic diseases requiring long-term systemic corticosteroid therapy, such as rheumatic or autoimmune diseases, that may interfere with ICS treatment and study outcomes.
- Pregnancy or Lactation:
- Pregnant or breastfeeding women are excluded due to the unclear risks of ICS treatment and anxiety management interventions in these populations.
- Allergic Bronchopulmonary Aspergillosis (ABPA) or Related Conditions:
- Diagnosed ABPA or other respiratory diseases with mechanisms distinct from asthma, which could confound the assessment of ICS treatment effects.
- Participation in Other Interventional Clinical Trials:
- Participation in another interventional clinical trial within the past three months, particularly those involving respiratory diseases or medication adherence management, to avoid confounding effects on outcomes.
- Incompatibility with Telephone-Based Interventions:
- Inability to reliably receive or engage in telephone-based psychological interventions due to hearing impairments, communication barriers, or other reasons.
- Adverse Reactions to Psychological Interventions:
- Documented refusal of or adverse reactions to psychological interventions, such as phone-based relaxation or motivational interviewing, that could affect the feasibility and effectiveness of the study.
- History of Major Surgery or Hospitalization:
- History of major surgery or hospitalization (unrelated to asthma) within the past six months that might impact current health status and introduce bias into the study outcomes.
Trial locations and contacts
11 sites in 1 country. Contact the study team or a site near you to ask about taking part.
11 sites in 1 country
China11 sites, 11 recruiting
- Recruiting
Second Affiliated Hospital of Harbin Medical University
Harbin
Dongju Su, 0451-86605222, hydsdj@126.com
- Recruiting
Anhui Chest Hospital
Hefei
Wenjuan Xia, 0551-63633507, wenjuanx616@163.com
- Recruiting
The First Affiliated Hospital of Anhui Medical University
Hefei
Ran Wang, 0551-62922114, wangran@ahmu.edu.cn
- Recruiting
The Second Affiliated Hospital of Anhui Medical University
Hefei
Jing Ye, 0551-63869420, plowchan@126.com
- Recruiting
Jingzhou Central Hospital
Jingzhou
Li He, 0716-8438516, hehel82@163.com
- Not yet recruiting
Haishu District People's Hospital
Ningbo
Jinggang Xu, 0574-87559778, 958813728@qq.com
- Recruiting
Ningbo Medical Center Lihuili Hospital
Ningbo
Biyun Yu, 0574-55836114, ybyfish@163.com
- Recruiting
Qianhu Hospital
Ningbo
Xingyu Liang, 0574-88490111, dr.liangxingyu@foxmail.com
- Recruiting
The First Affiliated Hospital of Ningbo University
Ningbo
Chao Cao, 0574-87085151, caocdoctor@163.com
- Recruiting
Ninghai County First Hospital
Ninghai
Min Ji, 531668993@qq.com
- Not yet recruiting
Taizhou Central Hospital
Taizhou
Xi Yang, 0576-88526000, yangx0603@tzzxyy.com
About this study
Official title: Remote Management Strategies and Adherence Improvement for Anxiety-related ICS Resistance in Asthma Patients: an Open-label, Multicenter, Randomized Controlled Trial
This study, the Remote Anxiety Management for ICS-resistant Asthma Study (RAMICS), explores strategies to improve medication adherence and anxiety management in asthma patients who are resistant to using inhaled corticosteroids (ICS) due to anxiety. Asthma is a chronic respiratory disease affecting millions worldwide, and ICS therapy is essential for controlling symptoms and preventing severe exacerbations. However, many patients struggle with adherence, especially those with anxiety about ICS side effects. RAMICS is a multicenter, open-label, randomized controlled trial designed to evaluate the effectiveness of personalized telephone-based interventions, including medication education, progressive muscle relaxation (PMR), motivational interviewing (MI), and lung rehabilitation guidance. The study will enroll 216 adult asthma patients with poor ICS adherence and clinically significant anxiety. Participants will be randomized into two groups: the intervention group, receiving weekly telephone sessions, and the control group, receiving standard follow-up calls. The study aims to assess improvements in ICS adherence, reductions in anxiety and depression, better asthma symptom control, and enhanced quality of life. Outcomes will be evaluated immediately after the 8-week intervention and during a 3-month follow-up. By addressing both psychological and medication adherence challenges, this research aims to provide practical solutions for improving asthma management.
- Conditions
- Asthma
- Being tested
- Personalized Telephone-Based Psychological Support, Standard Care with Weekly Follow-Up Calls
- Medical subject headings
- Asthma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Personalized Telephone-Based Psychological SupportBehavioural
This intervention involves weekly, individualized 30-minute telephone sessions conducted over 8 weeks. The sessions are designed to address anxiety and improve adherence to inhaled corticosteroid (ICS) therapy in asthma patients. The intervention comprises four core components:
- Medication Education: Detailed guidance on the benefits, mechanisms, and safety of ICS therapy, aiming to address misconceptions and reduce fears about side effects.
- Lung Rehabilitation Guidance: Instructions for breathing exercises and tailored physical activity to improve respiratory health and overall well-being.
- Motivational Interviewing (MI): A patient-centered approach that identifies barriers to adherence, enhances self-efficacy, and motivates behavior change.
- Progressive Muscle Relaxation (PMR): A systematic relaxation technique to alleviate physical and emotional stress, tailored to each patient's anxiety levels.
Standard Care with Weekly Follow-Up CallsBehavioural
Participants receive weekly telephone follow-up calls for 8 weeks. These calls include health status assessments, symptom monitoring, and general medication inquiries but exclude psychological or educational components.
| Study group | Role | What they receive |
|---|---|---|
| Personalized telephone-based psychological support | Experimental | Participants in this group will receive weekly, personalized 30-minute telephone sessions for 8 weeks, including medication education, lung rehabilitation guidance, motivational interviewing (MI), and progressive muscle relaxation (PMR). Receives: Behavioral: Personalized Telephone-Based Psychological Support |
| Standard Care with Weekly Follow-Up Calls | Placebo comparator | Participants in this group will receive weekly standard care calls for 8 weeks, focusing on health status, asthma symptoms, and medication use, without psychological or educational interventions. Receives: Behavioral: Standard Care with Weekly Follow-Up Calls |
What is being measured
The primary outcome is the main question the study is designed to answer.
ICS Adherence
Medication adherence will be assessed using the Medication Adherence Report Scale (MARS-10), a validated questionnaire. The scale includes 10 items, each scored from 1 (always) to 5 (never), with total scores ranging from 10 to 50. Higher scores indicate better adherence, and a mean score of ≥4.5 reflects good adherence.
Measured: Baseline, Week 4 (mid-intervention), Week 8 (end of intervention), and 3-month follow-up.
Secondary outcomes (14)
Anxiety Levels
Anxiety symptoms will be assessed using the Hamilton Anxiety Rating Scale (HAMA), a validated scale with scores ranging from 0 to 56, where higher scores indicate greater anxiety severity. The intervention aims to reduce anxiety related to ICS use through techniques such as progressive muscle relaxation (PMR) and motivational interviewing (MI).
Measured: Baseline, Week 4 (mid-intervention), Week 8 (end of intervention), and 3-month follow-up.
Depression Levels
Depressive symptoms will be observed using the Hamilton Depression Rating Scale (HAMD), which scores from 0 to 52, with higher scores indicating more severe depression. While the intervention may indirectly impact depressive symptoms, its specific effect on depression is not a primary focus and will require further investigation.
Measured: Baseline, Week 4 (mid-intervention), Week 8 (end of intervention), and 3-month follow-up.
Asthma Control Levels
Asthma symptom control will be assessed using the Asthma Control Test (ACT), a validated questionnaire with scores ranging from 5 to 25. Higher scores indicate better asthma control. The intervention aims to improve asthma control by enhancing ICS adherence and addressing anxiety-related barriers.
Measured: Baseline, Week 4 (mid-intervention), Week 8 (end of intervention), and 3-month follow-up.
Asthma-Related Quality of Life
Health-related quality of life will be evaluated using the Asthma Quality of Life Questionnaire (AQLQ), which measures the impact of asthma on daily activities, social interactions, and overall health perception. The scores range from 1 to 7, with higher scores indicating a better quality of life. The intervention aims to enhance patients' ability to manage asthma and reduce its negative impact on their quality of life.
Measured: Baseline, Week 4 (mid-intervention), Week 8 (end of intervention), and 3-month follow-up.
Incidence of Serious Adverse Events (SAEs)
The safety of the intervention will be assessed by monitoring and recording the incidence of treatment-emergent serious adverse events (SAEs) using the Serious Adverse Event Report Form (SAE Report). The research team will document, analyze, and provide appropriate medical responses to any incidents related to the intervention.
Measured: Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, and 3-month follow-up.
Intervention Adherence
Intervention adherence will be assessed using the Intervention Participation Record, documenting whether participants complete each scheduled telephone session. For the intervention group, adherence to weekly components such as medication education, PMR, and MI will be tracked. For the control group, participation in routine follow-up calls will be recorded.
Measured: Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8.
Asthma Exacerbation Events
Asthma exacerbation events will be assessed using the Asthma Exacerbation Record, documenting the time, frequency, and severity of each episode. Severity will be graded as mild, moderate, or severe based on international asthma management guidelines. The intervention's effectiveness in reducing exacerbation events will be analyzed.
Measured: Week 4 (mid-intervention), Week 8 (end of intervention), and 3-month follow-up.
Frequency of Emergency Department Visits
The number of emergency department visits due to asthma exacerbations will be tracked using patient self-reports and verified through medical records. This measure assesses the effectiveness of the intervention in reducing the reliance on acute emergency care.
Measured: Week 4 (mid-intervention), Week 8 (end of intervention), and 3-month follow-up.
Frequency of Hospitalizations
The number of hospital admissions due to asthma exacerbations will be documented, including details such as length of stay and treatments administered. This outcome evaluates the intervention's impact on reducing the necessity for inpatient care.
Measured: Week 4 (mid-intervention), Week 8 (end of intervention), and 3-month follow-up.
Occurrence of Respiratory Failure
Documentation of respiratory failure events during hospital stays, including clinical criteria for diagnosis and management details.
Measured: Week 4 (mid-intervention), Week 8 (end of intervention), and 3-month follow-up.
Use of Non-Invasive Ventilation
Documentation of the use of non-invasive ventilation during hospitalization, including indications and duration of use.
Measured: Week 4 (mid-intervention), Week 8 (end of intervention), and 3-month follow-up.
ICU Admission and Intubation
Records of ICU admissions and whether intubation was required during hospitalization, including associated clinical details.
Measured: Week 4 (mid-intervention), Week 8 (end of intervention), and 3-month follow-up.
Systemic Steroid Use
Documentation of systemic corticosteroid use during hospital stays, including dosage and duration.
Measured: Week 4 (mid-intervention), Week 8 (end of intervention), and 3-month follow-up.
Length of Hospital Stay
Total duration of each hospital stay will be recorded to assess the impact of the intervention on hospitalization length.
Measured: Week 4 (mid-intervention), Week 8 (end of intervention), and 3-month follow-up.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Dec 2024
- Study start13 Dec 2024
- Primary completion28 Feb 2027 (estimated)
- Study completion30 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AsthmaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 216 participants (estimated)
Sponsor and investigators
- Lead sponsor
- First Affiliated Hospital of Ningbo University
- Sponsor type
- Research network
- Responsible party
- Principal investigator, Chao Cao, Ph.D., First Affiliated Hospital of Ningbo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06732141
- Sponsor's protocol ID
- 2024-141A-02
- Acronym
- RAMICS
- Status last verified
- Jun 2026
- First submitted
- 9 Dec 2024
- Last updated
- 18 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Remote Management Strategies and Adherence Improvement for Anxiety-related ICS Resistance in Asthma Patients: an Open-label, Multicenter, Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT06732141
- Acronym / sponsor ID
- RAMICS / 2024-141A-02
- Conditions
- Asthma
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 216 participants (estimated)
- Lead sponsor
- First Affiliated Hospital of Ningbo UniversityResearch network
- Study start
- 13 Dec 2024 (actual)
- Primary completion
- 28 Feb 2027 (estimated)
- Study completion
- 30 Jun 2027 (estimated)
- First posted
- 13 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study, the Remote Anxiety Management for ICS-resistant Asthma Study (RAMICS), explores strategies to improve medication adherence and anxiety management in asthma patients who are resistant to using inhaled corticosteroids (ICS) due to anxiety. Asthma is a chronic respiratory disease affecting millions worldwide, and ICS therapy is essential for controlling symptoms and preventing severe exacerbations. However, many patients struggle with adherence, especially those with anxiety about ICS side effects. RAMICS is a multicenter, open-label, randomized controlled trial designed to evaluate the effectiveness of personalized telephone-based interventions, including medication education, progressive muscle relaxation (PMR), motivational interviewing (MI), and lung rehabilitation guidance. The study will enroll 216 adult asthma patients with poor ICS adherence and clinically significant anxiety. Participants will be randomized into two groups: the intervention group, receiving weekly telephone sessions, and the control group, receiving standard follow-up calls. The study aims to assess improvements in ICS adherence, reductions in anxiety and depression, better asthma symptom control, and enhanced quality of life. Outcomes will be evaluated immediately after the 8-week intervention and during a 3-month follow-up. By addressing both psychological and medication adherence challenges, this research aims to provide practical solutions for improving asthma management.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Personalized telephone-based psychological support | Experimental | Behavioral: Personalized Telephone-Based Psychological SupportParticipants in this group will receive weekly, personalized 30-minute telephone sessions for 8 weeks, including medication education, lung rehabilitation guidance, motivational interviewing (MI), and progressive muscle relaxation (PMR). |
| Standard Care with Weekly Follow-Up Calls | Placebo comparator | Behavioral: Standard Care with Weekly Follow-Up CallsParticipants in this group will receive weekly standard care calls for 8 weeks, focusing on health status, asthma symptoms, and medication use, without psychological or educational interventions. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (17 listed)
- Age Requirement:
- Participants must be aged 18 to 80 years, ensuring they are adults capable of making decisions and responding effectively to interventions.
- Diagnosed Asthma:
- ICS Treatment History:
- Poor Medication Adherence:
Key exclusion criteria (21 listed)
- Severe Psychiatric or Cognitive Disorders:
- Substance Abuse or Dependence:
- History of alcohol or drug abuse within the past six months, including but not limited to opioids, benzodiazepines, or illicit substances.
- Severe Comorbidities:
- Pregnancy or Lactation:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Personalized Telephone-Based Psychological SupportThis intervention involves weekly, individualized 30-minute telephone sessions conducted over 8 weeks. The sessions are designed to address anxiety and improve adherence to inhaled corticosteroid (ICS) therapy in asthma patients. The intervention comprises four core components: 1. Medication Education: Detailed guidance on the benefits, mechanisms, and safety of ICS therapy, aiming to address misconceptions and reduce fears about side effects. 2. Lung Rehabilitation Guidance: Instructions for breathing exercises and tailored physical activity to improve respiratory health and overall well-being. 3. Motivational Interviewing (MI): A patient-centered approach that identifies barriers to adherence, enhances self-efficacy, and motivates behavior change. 4. Progressive Muscle Relaxation (PMR): A systematic relaxation technique to alleviate physical and emotional stress, tailored to each patient's anxiety levels. | Behavioural | Personalized telephone-based psychological support |
| Standard Care with Weekly Follow-Up CallsParticipants receive weekly telephone follow-up calls for 8 weeks. These calls include health status assessments, symptom monitoring, and general medication inquiries but exclude psychological or educational components. | Behavioural | Standard Care with Weekly Follow-Up Calls |
Primary outcome
ICS Adherence
Time frame: Baseline, Week 4 (mid-intervention), Week 8 (end of intervention), and 3-month follow-up.
Medication adherence will be assessed using the Medication Adherence Report Scale (MARS-10), a validated questionnaire. The scale includes 10 items, each scored from 1 (always) to 5 (never), with total scores ranging from 10 to 50. Higher scores indicate better adherence, and a mean score of ≥4.5 reflects good adherence.
14 secondary outcomes
Anxiety Levels
Time frame: Baseline, Week 4 (mid-intervention), Week 8 (end of intervention), and 3-month follow-up.
Depression Levels
Time frame: Baseline, Week 4 (mid-intervention), Week 8 (end of intervention), and 3-month follow-up.
Asthma Control Levels
Time frame: Baseline, Week 4 (mid-intervention), Week 8 (end of intervention), and 3-month follow-up.
Asthma-Related Quality of Life
Time frame: Baseline, Week 4 (mid-intervention), Week 8 (end of intervention), and 3-month follow-up.
Incidence of Serious Adverse Events (SAEs)
Time frame: Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, and 3-month follow-up.
Intervention Adherence
Time frame: Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8.
Asthma Exacerbation Events
Time frame: Week 4 (mid-intervention), Week 8 (end of intervention), and 3-month follow-up.
Frequency of Emergency Department Visits
Time frame: Week 4 (mid-intervention), Week 8 (end of intervention), and 3-month follow-up.
Frequency of Hospitalizations
Time frame: Week 4 (mid-intervention), Week 8 (end of intervention), and 3-month follow-up.
Occurrence of Respiratory Failure
Time frame: Week 4 (mid-intervention), Week 8 (end of intervention), and 3-month follow-up.
Use of Non-Invasive Ventilation
Time frame: Week 4 (mid-intervention), Week 8 (end of intervention), and 3-month follow-up.
ICU Admission and Intubation
Time frame: Week 4 (mid-intervention), Week 8 (end of intervention), and 3-month follow-up.
Systemic Steroid Use
Time frame: Week 4 (mid-intervention), Week 8 (end of intervention), and 3-month follow-up.
Length of Hospital Stay
Time frame: Week 4 (mid-intervention), Week 8 (end of intervention), and 3-month follow-up.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Asthma
Recruiting
Lungs on Fire: Wildfire Smoke, Incident Diseases, Susceptible Populations, and Community Values in Canada
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
RecruitingObservational study
Study of the Effect of Innate on the Inflammatory Response to Endotoxin
Asthma, Atherosclerosis
Not yet recruitingObservational study
Prevelance of Broncial Asthma and Allergic Rhinitis in Children With Nephrotic Syndrim
Bronchial Asthma, Allergic Rhinitis
Enrolling by invitationObservational study
Firefighter's Longitudinal Airway and Respiratory Exposome/Multiome Study (FLARES)
Anosmia, Chronic Obstructive Pulmonary Disease
Active, not recruitingPhase 2
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
Asthma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
11 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Personalized Telephone-Based Psychological Support in people with Asthma, run by First Affiliated Hospital of Ningbo University at 11 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 17 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 18 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 11 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Chao Cao (+86-0574-87089878, caocdoctor@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
ICS Adherence (time frame: Baseline, Week 4 (mid-intervention), Week 8 (end of intervention), and 3-month follow-up.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2026.